Physician profile
John C Veltman
NPI 1740239771
$14,524.96
in general payments reported to CMS, 2019-2025
39 companies · $627 in 2025
The $627 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,069 · 2020: $2,099 · 2021: $3,562 · 2022: $2,376 · 2023: $1,216 · 2024: $1,577 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,559.52 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,755.77 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceuticals, INC. | $1,644.67 | 2021 | |
| Novo Nordisk INC | $1,120.96 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $708.05 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $511.49 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $462.48 | 2023-2025 | Voquezna |
| Eisai INC. | $422.21 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.06 | 2019-2023 | Synjardy, Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $404.97 | 2022 | |
| Amgen INC. | $385.21 | 2019-2023 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $373.52 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $337.76 | 2019-2021 | |
| Abbott Laboratories | $328.22 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $321.33 | 2021-2025 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Veltman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.